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Abstract
Background: Novel and robust cardiovascular (CV) markers are needed to improve CV morbidity and mortality risk
prediction in type 2 diabetes (T2D). We assessed the long term predictive value of 4 novel CV risk markers for major
CV events and mortality.
Methods: We included patients with T2D who had cytokines (interleukin [IL]-6 and activin A [actA]), a maximum
stress ECG test (evaluated by the normalization pattern in early recovery phase) and echocardiography (evaluated
by a measure of the left ventricular filling pressure - E/Em) assessed at baseline. The primary endpoint was time to
first of any of the following events: myocardial infarction, stroke, hospitalization for unstable angina pectoris and
death. All outcomes were adjudicated by independent experts. We used Cox proportional hazard modeling, Harrell
C-statistic and the net reclassification improvement (NRI) to assess the additional value beyond conventional
markers (age, gender, prior CV disease, HDL, creatinine, diastolic BP, microalbuminuria).
Results: At baseline the study cohort (n = 135, mean age/diabetes duration/HbA1c: 59 yrs/7 yrs/7.6% [59 mmol/mol],
26% females) had moderate elevated CV risk (42% microalbuminuria, mean Framingham 10 year CV-risk 9.6%). During
8.6 yrs/1153.7 person years, 26 patients experienced 36 events. All 4 novel risk markers were significantly associated with
increased risk of the primary endpoint, however, only IL-6 and actA improved C-statistic and NRI (+0.119/43.2%, +0.065/
20.3% respectively) compared with the conventional CV risk factors.
Conclusions: IL-6 and actA may provide prognostic information on CV events and mortality in T2D beyond conventional
CV risk factors.
Trial registration: ClinicalTrials.gov: NCT00133718
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Introduction
Individuals with type 2 diabetes are at high risk for devel-
oping cardiovascular disease (CVD), such as coronary ar-
tery disease (CAD) and stroke, and CVD is recognized as
the leading cause of premature death in people with type 2
diabetes [1]. Although state-of-the-art follow-up, including
primary and secondary prevention, has reduced the car-
diovascular (CV) incidence in individuals with type 2 dia-
betes, considerable residual CV risk remains. Therefore,
together with increasing longevity, the CV burden for soci-
eties remains substantial [2]. One particular challenge in
diabetes is that detection of CVD, in particular of CAD, is
difficult due to atypical symptoms as well as a low sensiti-
vity inherent in traditional non-invasive tests such as exer-
cise ECG test or scintigraphy [3]. Moreover, although
certain biomarkers have held the promise to improve CV
risk prediction in people with type 2 diabetes, their appli-
cability and implementation currently are not widespread.
Novel, preferable, non-invasive tests (functional or struc-
tural) and markers (blood or urine) are therefore needed
to enable earlier identification of individuals with type 2
diabetes at high risk for CVD.
Exercise ECG is frequently used to diagnose CAD in
subjects with type 2 diabetes, however with lower sensiti-
vity than in non-diabetic subjects. An evaluation of the
early recovery phase of an ECG stress-test may potentially
provide insight into the interplay between physiology and
pathology [4,5] and our group has previously shown that
detection of a pathological normalization of this phase im-
proves sensitivity of an ECG stress test [6]. Based on these
data, we hypothesized that detection of a pathological re-
covery phase would improve prediction of adverse out-
come in people with type 2 diabetes. Another functional
parameter, readily available from a conventional echocardi-
ography examination, is the ratio E/Em which describes the
ratio between early diastolic transmitral flow velocity and
early diastolic mitral annular velocity. E/Em is a sensitive,
non-invasive measure of the left ventricular end diastolic fil-
ling pressure in selected populations [7] and has been found
to be independently associated with mortality and CV
events in several disease condititions [8-10]. Since patients
with type 2 diabetes are prone to develop left ventricular
diastolic dysfunction, which often evolves over several
years before symptoms occur [11], we hypothezised that
E/Em could provide prognostic information also in this
population.
In addition to novel approaches in ECG- and echocar-
diography assessment, soluble biomarkers have received
much attention in CVD [12-15]. A large mendelian
randomization analysis [15] found evidence for a causal
role of IL-6 receptor signalling in the development of
CAD, and proposed blockage of the IL-6 receptor as a
novel therapeutic approach to prevent CAD. Our group
has previously shown that interleukin (IL)-6 and activin A,
a member of the transforming growth factor β superfamily,
are related to the degree of CAD in patients with type 2
diabetes [16,17].
In the present study, in individuals with type 2 diabetes,
we explored the association of these novel CV risk markers
(pathological recovery phase, E/Em, IL-6 and activin A)
with major CV events and mortality.
Research design and methods
Study population and study design
The present longitudinal, cohort study is part of the pro-
spective study Asker and Bærum Cardiovascular Diabetes
(ABCD) study (clinical trials.gov id: NCT00133718) that
was initiated in 2002. In short, 135 patients with type 2 dia-
betes were recruited over 2 years (2002–2004) and under-
went a comprehensive diagnostic work-up at baseline (BL)
including medical history and physical examination, labora-
tory assessment including markers of inflammation, renal
function and lipids, urinary assessment of albumin excre-
tion, ECG, cardiopulmonary exercise test (CPET) with spe-
cial emphasis on the recovery phase (ST/HR-recovery loop
evaluation), echocardiography including tissue Doppler Im-
aging (TDI), and invasive coronary angiography.
Our primary composite endpoint was time to death
or first CV event (myocardial infarction [MI], stroke or
hospitalization for unstable angina pectoris [UAP]). All
clinical events were adjudicated by an independent
endpoint committee. During the first two years of the
study, 120 of the 135 patients participated in a two year
program comparing usual care provided by general
practitioners to intensive structured care at the diabetic
out-patient clinic. At the end of the 2 year program, all
study participants were transferred back to pre-inclusion
care and recommended follow-up according to guidelines.
Informed consent was obtained from all participants.
The study was conducted in accordance with the Helsinki
declaration and good clinical practice and was approved
by the Regional Ethical Committee.
Biochemical analyses in blood
Routine laboratory parameters were assessed in periph-
eral venous blood drawn in the morning after an over-
night fast and immediately analyzed by the local
laboratory (described in details previously [16]). Plasma
levels of IL-6 and serum levels of activin A were analyzed
by immunoassays from R&D Systems (Minneapolis, Minn.,
USA) and Serotec (Oxford, UK) as previously described
[16,17]. Serum levels of high sensitivity C-reactive protein
(hsCRP) were analyzed by a high-sensitivity, particle-
enhanced, immunoturbidimetric assay on a modulator
platform (Roche Diagnostica, Basel, Switzerland). For all
assays, the intra-and interassay coefficients of variation
were < 10%.
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Urinary samples
Urinary albumin excretion was determined in timed over-
nights urine samples. Micro-albuminuria was defined as
urinary excretion > 20 μg/min in two out of three samples
[18].
Exercise testing
Exercise capacity was assessed by a modified conventional
maximum symptom-limited cardiopulmonary exercise test
on a cycle ergometer as described previously [16]. The ST/
heart rate (HR)-slope was computer calculated using linear
regression of all ST-amplitude and HR-data (obtained every
10th second) during the last 4 minutes of exercise. The com-
puter generated ST/HR- recovery loop was then evaluated
in the same lead and semi-quantitatively classified to be
counterclockwise (normal) or clockwise or figure 8 loop
(pathological).
Coronary angiography
Coronary angiography was performed in 91 patients
according to standard procedures irrespective of re-
sults from non-invasive tests [16]. Significant CAD was
defined as the presence of ≥ 50% luminal diameter
narrowing of one or more of the epicardial arteries or
its major branches.
Echocardiography
Transthoracic echocardiography was obtained in 100
consenting patients by experienced research echocardiog-
raphers following guidelines for acquisition and interpret-
ation of data [19,20] using GE Vingmed Ultrasound’s Vivid
5 or 7 with a 2.5 MHz probe (Horten, Norway). Pulsed
wave Doppler mitral flow velocities were recorded in the
apical 4-chamber view with the sample volume between
the leaflet tips. In the same view, color-coded Tissue Dop-
pler Imaging (TDI) loops were recorded and stored digitally
and the early diastolic mitral annular velocity (Em) was
measured off-line in the basal interventricular septum
(EchoPac, GE Vingmed Ultrasound AS).
Statistics
Based on the STENO-2 study (~ 715 patient years of
follow-up) [21], we targeted at least 1000 patient years of
follow-up to ensure that the predictive properties of the
novel risk factors and tests could be assessed with a rea-
sonable power. We used the two-sample T test to compare
continuous variables. Microalbuminuria, activin A and
hsCRP were log-transformed due to their skewed distribu-
tions. The Pearson chi-square test and the Fisher mid-p
test were used to compare dichotomous variables [22].
We explored the relation of biomarkers to outcome
with Cox proportional hazards models. The following var-
iables were considered for inclusion in adjusted models:
age, diabetes duration, gender, known history of CVD i.e.,
CAD, stroke or peripheral artery disease, at inclusion, alloca-
tion to treatment group first 2 study years (see methods),
systolic blood pressure (BP), diastolic BP, HDL cholesterol,
LDL cholesterol, HbA1c, creatinine, body mass index (BMI),
smoking, microalbuminuria, left ventricle internal diastolic
diameter, end diastolic volume index, and LV ejection frac-
tion (LVEF)). Variables with p > 0.25 in univariable analyses
were excluded from the final adjusted models. We assessed
the proportional hazards assumption by a test based on
Schoenfeld’s residuals.
To explore the additional predictive value of the new risk
markers, we used Harrell’s C-statistic and the Net Reclassifi-
cation Improvement (NRI) [23]. Three risk categories (de-
fined by 5% and 10% cut-offs of estimated probabilities from
logistic regression models) were used to calculate the NRI-
values. We used SPSS version 18.0 (SPSS Inc., Chicago, IL)
and STATA version 12 (StataCorp, College Station, TX) for
statistical analysis. In all analyses, p < 0.05 was considered
significant.
Results
The observational period, which started in 2002, ended
May 29th 2012 and of the 135 patients that were
enrolled and comprehensively assessed at BL, three
patients (2.2%) were lost to follow-up, rendering 132 pa-
tients with information on outcome and vital status at
study end. In two cases, cause of death was lacking in
the medical records, and information was obtained
from the Norwegian National Death Registry. During a
follow-up time of 8.6 ± 2.1 years corresponding to 1153
person years, 26 patients (19.3%) experienced a total of
36 events (8 MIs, 8 strokes, 3 hospitalizations for UAP,
5 CV deaths and 12 non-CV deaths [3 cancers, 2 infec-
tions, 1 Parkinson’s Disease, 1 acute renal failure, 1 opi-
oid overdose and 1 gangrenous colon due to embolies])
translating to an event rate of 3.12 and a crude mortal-
ity rate of 1.47 pr 100 person years.
Baseline characteristics stratified by outcome are given in
Table 1 and Figure 1A-E. Patients who experienced an
event were significantly older, had higher proportions of 2-
or 3-vessel CAD, had more often known CAD or CVD at
inclusion, had higher serum level of creatinine, lower LVEF
and a higher Framingham risk score. In addition, these pa-
tients more often had a pathological recovery-loop as well
as higher levels of IL-6, activin A and E/Em. In contrast,
there were no differences in hsCRP, lipid parameters,
HbA1c and microalbuminuria between these two groups
of type 2 diabetes patients (Table 1, Figure 1A-E).
In a univariate Cox regression analysis, IL-6, activin A,
E/Em and pathological recovery-loop, but not CRP (data
not shown), were all significantly associated with the out-
come (Figure 2). Several conventional risk factors were
also significantly associated with outcome in univariate
analysis: age (HR = 1.08, 95% CI 1.03-1.13), known history
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of CVD at inclusion (HR = 3.53, 95% CI 1.58-7.87) and
creatinine (HR = 1.41, 95% CI 1.09-1.82).
Activin A and IL-6 (also when dichotomized at median
values, respectively IL-6 > 0.6 pg/mL and activin A > 0.56
ng/mL), but not E/Em and pathological recovery loop
maintained their predictive value when adjusted for the
conventional risk factors (age, gender, known CV disease,
diastolic blood pressure, microalbuminuria and serum
levels of HDL-cholesterol and creatinine) in multivariate
analysis (Figure 2). Table 2 shows C-statistics and NRI for
our conventional risk factors (clinical and biochemical)
and different combinations of novel biomarkers on top of
this standard model. Two of the explored novel markers
(i.e., IL-6 and activin A) significantly improved risk classi-
fication in this study cohort and fitted overall with the re-
sults from the Cox regression. Moreover, when combining
these two markers, we observed a 47% improvement in
risk classification.
Discussion
Our main findings in the present study were that the novel
risk markers and tests IL-6, activin A, pathological reco-
very loop and E/Em all were significantly associated with a
combined endpoint of CV events and mortality in a co-
hort of patients with type 2 diabetes at moderate CV risk.
For IL-6 and activin A, the association to CV events and
mortality was kept when adjusting for traditional CV risk
factors. Also, when added to a model based on traditional
risk factors, IL-6 and activin A, but not E/Em or post-
exercise recovery loop, improved risk classification beyond
conventional CV risk factors as assessed by C-statistics
and NRI.
Table 1 Demographics, traditional CV risk factors, comorbidities and the use of medication at baseline, stratified by outcome
All (n = 135) Patients with event (n = 26) Patients without event (n = 109) P value
Conventional CV risk markers
Age (yrs) 58.5 ± 10.0 64.2 ± 8.6 57.2 ± 9.9 0.001
Females n (%) 35 (26) 29 (27) 6 (23) 0.81
Diabetes duration (yrs) 6.5 ± 6.3 5.6 ± 4.8 6.6 ± 6.4 0.46
BMI (kg/m2) 30.0 ± 5.4 29.7 ± 6.2 30.1 ± 5.2 0.75
Systolic BP (mmHg) 142 ± 20 144 ± 21 142 ± 20 0.60
Diastolic BP (mmHg) 83 ± 10 83 ± 13 83 ± 9 0.81
HbA1c (%/mmol/mol) 7.6 ± 1.6/59.3 ± 17.0 7.5 ± 1.6/58.3 ± 17.0 7.6 ± 1.6/59.6 ± 17.1 0.74
FBG (mmol/L) 9.5 ± 3.2 9.4 ± 3.2 9.6 ± 3.3 0.80
Total cholesterol (mmol/L) 4.9 ± 1.0 4.8 ± 1.4 5.0 ± 1.0 0.47
LDL cholesterol (mmol/L) 2.8 ± 0.9 2.7 ± 0.8 2.9 ± 0.9 0.23
HDL cholesterol (mmol/L) 1.3 ± 0.4 1.2 ± 0.3 1.3 ± 0.4 0.29
Triglycerides (mmol/L) 1.9 ± 1.8 2.2 ± 3.2 1.8 ± 1.2 0.56
Creatinine (μmol/L) 78.5 ± 15.3 86.7 ± 21.1 76.5 ± 12.9 0.025
Albuminuria (μg/min) 16.0 (9.0, 30.5) 22.0 (9.8, 39.0) 15.0 (9.0, 28.3) 0.091
Microalbuminuria n (%) 56 (42) 14 (54) 42 (39) 0.17
LVEF (%) 63 ± 8 59 ± 8 64 ± 8 0.029
Daily smoking n (%) 16 (12) 3 (12) 13 (12) 0.87
Known CAD at inclusion n (%) 16 (12) 8 (31) 8 (7) 0.002
Known CVD at inclusion n (%)* 22 (16) 10 (39) 12 (11) 0.001
Framingham 10 years risk of CHD (%) 9.6 ± 6.6 12.7 ± 6.9 8.9 ± 6.4 0.022
Medications
Numbers of Blood glucose lowering medications 1.2 ± 0.9 1.4 ± 0.9 1.2 ± 0.9 0.29
Numbers of BP-lowering medications† 0.9 ± 1.0 1.1 ± 1.2 0.9 ± 1.0 0.39
On statins n (%) 61 (45) 14 (54) 47 (50) 0.38
On ASA n (%) 45 (33) 12 (46) 33 (30) 0.16
Data given as means ± SD, medians (interquartile range) or proportions.
Abbreviations: CV Cardiovascular, BMI Body mass index, BP Blood Pressure, FBG Fasting blood glucose, LVEF Left ventricular ejection fraction, CAD Coronary artery
disease, CVD Cardiovascular disease, CHD Coronary heart disease, ACEI Angiotensin-converting enzyme inhibitor, ARB Angiotensin II receptor blocker, ASA
Acetylsalicylic acid.
* = known history of CAD, stroke or peripheral artery disease at inclusion.
† = ACEI/ARBs/beta blockers/Ca-blockers/diuretics/combined therapy.
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Of interest is that IL-6 has emerged as an important cyto-
kine with a link to atherosclerosis and diabetes [24,25], and
evidence from two large genetic studies indicates causality
between IL-6 receptor signalling and CAD [15,26]. Sup-
portive to our results are the results by Martin-Cordero
et al. of increased levels of IL-6 in high CV risk rats (gene-
tically obese rats with metabolic syndrome) [27], and the
study by Zhou et al. which found increased levels of IL-6 in
epicardial tissue in humans with CAD [28], highlighting
this association. Further, longitudinal studies in healthy
post-menopausal women [29], healthy men [30] and elderly
[31] have shown the ability of IL-6 to be a predictor of fu-
ture CV events and mortality. However, data evaluating IL-
6’s long term ability to predict clinical outcomes in people
with type 2 diabetes is scarce. In a relatively small cross-
sectional study on men with type 2 diabetes, comparison of
different CV risk markers in patients with microvascular
complications with patients with established CAD [32], re-
vealed no significant difference in IL-6 levels. A German
group investigated the association between IL-6 and pri-
mary CV events in 1072 patients with type 2 diabetes dur-
ing 5 years follow-up and found a significant association
with adverse events [33]. Our study further indicates an
association between IL-6 and CV events and all cause
mortality in people with type 2 diabetes potentially giving
prognostic information beyond traditional risk factors.
Activin A exhibits both anti- and pro inflammatory ef-
fects [34] and has been implicated in the pathogenesis of
diabetes. It has also been related to CAD, potentially
reflecting a counteracting mechanism [35], and may re-
flect disease severity of type 2 diabetes [17,36,37]. The
present study further supports a role for activin A in dia-
betes and related CV events and death by showing an in-
dependent association between activin A and adverse
outcome in type 2 diabetes.
CRP is regarded as a reliable down-stream marker of in-
flammation, and although IL-6 is suggested to be one of
its main inducers, we could not find any association of
Figure 1 A-E: Novel cardiovascular risk markers stratified by outcome. The columns represent the mean ± SD [IL-6 and E/Em] or median (IQ
range) [activin A and hsCRP] levels of novel CV markers, or proportions of participants with pathological loop [pathological loop] in all
participants, in those who experienced a MACE or died, and in those who stayed event-free. *: p < 0.05, **: p < 0.01 event vs no event. SD =
standard deviation, IL-6 = Interleukin-6, hsCRP = high sensitivity C-reactive protein, CV = cardiovascular, MACE =major adverse cardiovascular event.
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CRP with CV events and death in this population with
type 2 diabetes. The reason for this finding is at present
not clear, but underscores that it is unlikely that one
marker could reflect all inflammatory pathways involved
in complex disorders like type 2 diabetes and its CV
complications. Moreover, although IL-6 is an up-stream
activator of CRP synthesis, this pleiotrophic cytokine
also has a wide range of other effects not related to in-
duction of acute phase proteins.
E/Em is a reliable predictor of major CV events and
death in chronic renal failure, ischemic heart disease and
in hypertrophic cardiomyopathy [8,9,38]. Our data indi-
cated that E/Em, an easily attainable ratio in those patients
that undergo echocardiography, is associated with major
CV events and death also in people with type 2 diabetes.
We did, however, not find a clear improvement in the
prediction of outcome when adding E/Em to a model
consisting of conventional CV risk factors, potentially at
least partly reflecting a relatively low number of patients.
Likewise, although we found that pathological recovery
loop was significantly associated to outcome, it did not
improve prediction of this beyond standard risk factor
assessment.
Limitations
Our study has some limitations including a potential low
generalizability since all patients were Caucasians and ex-
amined at the same center. The number of participants was
relatively low and not all had IL-6 and E/Em measured,
which led to an even more reduced number of events that
could be related to these markers and tests. Our study is
also insufficiently powered to analyze the individual compo-
nents of the composite endpoint in fatal and non-fatal CV
events. Moreover, less than 1/3 of the first events had car-
diac origin; the remaining being strokes, stroke related
deaths, or death from non CV causes.
The strength of our study is foremost the long observation-
time and accurate follow-up data on outcome, and that few
patients were lost to follow-up.
Conclusion
Circulating levels of IL-6 and activin A may provide prog-
nostic information on CV events and mortality beyond
Figure 2 Unadjusted and adjusted hazard ratios for major CV events and death for the novel CV risk markers. * adjusted for age, gender,
known CVD at inclusion, diastolic blood pressure, s-HDL-cholesterol, log microalbuminuria and s-creatinine. Abbreviations: CV = cardiovascular, IL-6 =
Interleukin-6, SD = Standard Deviation.
Table 2 C-statistics and net reclassification improvement
(NRI) for the conventional risk markers alone, and in
combination with one or more novel risk marker
Harrell’s C NRI, P-value
Standard (STD) model alone 0.794 Reference model
STD + IL-6 0.913 43.2%, p = 0.001
STD + log ActivinA 0.859 20.3%, p = 0.013
STD + IL-6 + log ActivinA 0.923 46.5%, p < 0.001
STD + E/Em + pathol recovery loop 0.891 21.5%, p = 0.099
The NRI calculations are based on estimated probabilities of event from
logistic regression models. The three risk categories used are defined by the
probability cut-offs 5% and 10%.
STD model: age, gender, known CVD, diastolic blood pressure,
microalbuminuria and serum levels of HDL-cholesterol and creatinine
Abbreviations: STD Standard, IL-6 Interleukin-6, pathol Pathological.
Ofstad et al. Cardiovascular Diabetology 2013, 12:126 Page 6 of 8
http://www.cardiab.com/content/12/1/126
traditional CV risk factors. As these both are easily
implementable in clinical practice they could improve CV
prevention strategies in people with type 2 diabetes. We
suggest that these parameters as well as E/Em and patho-
logical recovery loop should be further validated in other
and larger cohorts of patients with type 2 diabetes.
Abbreviations
MACE: Major adverse cardiovascular event; CV: Cardiovascular;
CVD: Cardiovascular disease; CAD: Coronary artery disease; IL: Interleukin;
CPET: Cardiopulmonary exercise test; TDI: Tissue doppler imaging;
MI: Myocardial infarction; UAP: Unstable angina pectoris; hsCRP: High
sensitivity C-reactive protein; ST/HR: ST/heart rate; LV: Left ventricular;
LVEF: Left ventricular ejection fraction; BMI: Body mass index; NRI: Net
reclassification improvement.
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